Subscribe free to our newsletters via your
. Earth Science News .

Early progress in antibody protection from deadly flu
by Staff Writers
Washington (AFP) May 29, 2013

Studies on lab animals have shown early success in a type of gene therapy that may prevent the spread of pandemic flu, including historic lethal strains from 1918 and 2009, researchers said Wednesday.

The method developed at the University of Pennsylvania School of Medicine delivered a broadly neutralizing flu antibody into the nasal passages of ferrets and mice, protecting them against potentially lethal flu.

The research is still in its initial stages, but could offer a new tool against influenza infections which kill 500,000 people globally each year, scientists said.

A single dose appeared to protect mice for as long as nine months against a range of flu strains, including three strains of H5N1, a deadly bird flu, and and two strains of H1N1, known widely as the "swine flu" that emerged in 2009.

Typically, influenza viruses evolve so rapidly that a new vaccine is created each year, offering only limited protection against the flu which can be lethal particularly in the elderly and those with weak immune systems.

The research published in the journal Science Translational Medicine did not experiment with the latest form of bird flu to emerge from China, H7N9, which has killed 37 of the 132 people infected since March.

According to a separate study in The Lancet on Tuesday, some H7N9 bird flu patients have already been found to be resistant existing antivirals, likely as a result of treatment with Tamiflu.

"The experiments described in our paper provide critical proof-of-concept in animals," said lead researcher James Wilson, of the department of pathology and laboratory medicine at the University of Pennsylvania.

"Further development of this approach for pandemic flu has taken on more urgency in light of the spreading infection in China of the lethal bird strain of H7N9 virus in humans."

Scientists cloned a gene that encodes an antibody that works against many strains of flu, then engineered cells that line the nasal passages and express a broadly neutralizing antibody that wards off flu.

The method uses adeno-associated virus vectors based on a primate virus, AAV9, to deliver broadly neutralizing antibodies to a section of the flu virus that is not believed to evolve as rapidly as other parts.

If the technique can be proven to work in people, its benefits would include speed of use against a pandemic -- which usually does not allow enough time to develop an effective treatment -- and a non-invasive, low cost application.

"Overall, the information is pretty useful," said Suresh Mittal, a professor of comparative pathobiology in Purdue's College of Veterinary Medicine, who was not involved in the research.

He said more needs to be done to determine the optimal dosage in humans, to find out how long the protective effects may last and if influenza can find a way to outsmart even a broadly neutralizing antibody.

"But as usual, once the new information comes in there will be a lot of other work that needs to be done," Mittal told AFP.

Clinical trials in humans to evaluate the use of adeno-associated virus vectors as gene delivery agents in cancer therapy are already under way.


Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola

Comment on this article via your Facebook, Yahoo, AOL, Hotmail login.

Share this article via these popular social media networks DiggDigg RedditReddit GoogleGoogle

Memory Foam Mattress Review
Newsletters :: SpaceDaily :: SpaceWar :: TerraDaily :: Energy Daily
XML Feeds :: Space News :: Earth News :: War News :: Solar Energy News

Confirmed cases of H7N9 bird flu drug resistance: study
Paris , France (AFP) May 28, 2013
Laboratory tests have revealed resistance in some H7N9 bird flu patients to the only available treatment, said virologists who unveiled "concerning" study results on Tuesday. Three out of 14 patients monitored at a clinic in Shanghai had a genetically-mutated version of the virus that makes it drug resistant, a team of researchers in China wrote in the journal The Lancet. Of the three, ... read more

Africa plans emergency force, but can it deliver?

Remembering storm, Obama, Christie again the odd couple

Bill Gates hopeful of more aid from China

Japan nuclear lab accident affected 30: agency

Helicopter-light-beams - a new tool for quantum optics

Just how secure is quantum cryptography

One Year Anniversary of KOMPSAT-3 Launch

Crystal-clear method for distinguishing between glass and fluids

Small dams on Chinese river harm environment more than expected

Source of life running out: water scientists

S. Korea commission to probe $20 bln river project

Spain and France agree on fishing quota swap

Russian scientists make rare find of 'blood' in mammoth

Study explores atmospheric impact of declining Arctic sea ice

The Antarctic polar icecap is 33.6 million years old

Slovenian flyer completes eco-friendly Arctic voyage

Even farm animal diversity is declining as accelerating species loss threatens humanity

China's Shuanghui to buy US pork icon Smithfield

Colombia peace still distant despite a first deal

New research shows that potatoes provide one of the best nutritional values per penny

Small earthquake rocks Wales

Hurricane Barbara hits land in Mexico, two dead

Chile begins evacuation near volcano

Massive Far East quake felt in Moscow, no casualties

Climate change drowning the 'Venice of Africa'

Outside View: Somalia's Jubaland

Nigeria says women, children held by Boko Haram freed

Africa celebrates progress and 50 years of 'unity'

Study: African terrain may have pushed humans into walking on two feet

170,000 living in subdivided flats in Hong Kong: study

Monkey teeth help reveal Neanderthal weaning

China newborn rescued from toilet pipe: report

The content herein, unless otherwise known to be public domain, are Copyright 1995-2014 - Space Media Network. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement,agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement